On June 23, 2023 Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported the appointment of Alethia Young as its new Chief Financial Officer, effective July 17th (Press release, Bicycle Therapeutics, JUN 23, 2023, View Source [SID1234632871]). Ms. Young joins Bicycle from Graphite Bio, where she served as Chief Financial Officer, and previously served as senior biotech analyst and head of research at Cantor Fitzgerald.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are thrilled to welcome Alethia to Bicycle and believe her experience and insights will make her an invaluable addition to our team," said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "Alethia is a seasoned expert in the biopharma industry, with her leadership position at Graphite and decade-plus of experience as a top biotech research analyst making her the ideal appointment as we continue to advance our clinical trials, prepare for commercialisation and head into our next phase of growth as a company."
Ms. Young commented, "I have been following the Bicycle story since covering them as a research analyst on the sell-side, and have been especially impressed by the recent clinical progress the team has made across their platform, from the Bicycle toxin conjugate (BTC) and Bicycle tumor-targeted immune cell agonist (Bicycle TICA) programs, to the newer addition of Bicycle radio-conjugates (BRCs). I look forward to working alongside the team to help patients in need of new treatment options, by moving forward the entire pipeline and expanding the potential applications of the Bicycle platform across oncology and beyond."
Dr. Lee added, "On behalf of our Board and the entire team at Bicycle, I want to thank Lee Kalowski for his contributions to the company. Lee, who served as Bicycle’s Chief Financial Officer since 2017, was instrumental in his work leading the company through its IPO and subsequent fundraisings, putting Bicycle in a strong financial position for our future."
Ms. Young has more than 20 years of experience in the healthcare and biotech industry. Prior to joining Graphite Bio as Chief Financial Officer in 2022, she served as senior biotech analyst and head of research at Cantor Fitzgerald, managing the equity research department covering small-cap, mid-cap and large-cap biotechnology companies. Before joining Cantor Fitzgerald in 2018, Ms. Young held senior biotech analyst positions at Credit Suisse and Deutsche Bank. Earlier in her career, she was a research policy analyst and president at Marwood Group, providing healthcare-focused advisory services to institutional investors. She began her career at J.P. Morgan in the investment banking and asset management divisions. She earned a B.A. in economics and Spanish from Duke University.
In addition, Bicycle announced the promotion of Travis Thompson, Senior Vice President, Finance, to Senior Vice President, Chief Accounting Officer. Mr. Thompson will work alongside Ms. Young, overseeing the company’s financial and accounting operations.